We are presenting the DIANA platform at 6th European Chemical Biology Symposium and the meeting of the EuChemS Division “Chemistry in Life Sciences” in Madrid at 3rd-5th April 2019. Meet us there to learn about DIANA’s potential in HTS screening and affinity profiling of Carbonic anhydrase inhibitors and discuss partnership opportunities.
We are presenting DIANA at SLAS 2019 in Washington DC 4th-6th February 2019. Meet us there to learn about DIANA’s potential in HTS screening and affinity profiling and discuss partnership opportunities.
The team of scientists at IOCB successfully used DIANA technology to screen for inhibitors of influenza neuraminidase. Their study has been published in Biochemical Journal. Kožíšek et al. (2019): DNA-linked inhibitor antibody assay (DIANA) as a new method for screening influenza neuraminidase inhibitors.
We are presenting DIANA at 2018 ELRIG Drug Discovery meeting in London 9th-10th October 2019. Meet us there to learn about DIANA’s potential in HTS screening and affinity profiling and discuss partnership opportunities in drug discovery.
IOCB spin-off company DIANA Biotechnologies, s.r.o. was founded with the significant venture capital funding from the BPD Partners group in order to deliver DIANA products to the market. The company, which is based in its own research facilities in Vestec near Prague, was granted the exclusive global license to develop commercial applications based on the DIANA and related … Read more
Václav Navrátil’s team has been awarded the prestigious Werner von Siemens Award for 2017 for the development of the DIANA technology. This prize, sponsored by Siemens, is awarded each year to the best innovation project in the Czech Republic.